UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 739

Sortiert nach

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

Diabetes, obesity & metabolism, 2016-03, Vol.18 (3), p.203-216

Nauck, M.

2016

Link zum Volltext

Verfügbarkeit prüfen

CO-28: Comparaison de l'efficacité du liraglutide à celle du lixisenatide en ajout de metformine chez des patients diabétiques de type 2 : essai randomisé contrôlé de 26 semaines

Diabetes & metabolism, 2016-03, Vol.42, p.A9-A9

2016

Link zum Volltext

Verfügbarkeit prüfen

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down

Diabetologia, 2011, Vol.54 (1), p.10-18

2011

Link zum Volltext

Verfügbarkeit prüfen

comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

Diabetologia, 2007-02, Vol.50 (2), p.259-267

2007

Link zum Volltext

Verfügbarkeit prüfen

P292 Efficacité et tolérance de l’adjonction du liraglutide à une insuline basale en comparaison au placebo chez des patients diabétiques de type 2 (résultats de l’essai randomisé contrôlé LIRA-ADD2BASAL)

Diabetes & metabolism, 2015-03, Vol.41, p.A106-A107

2015

Link zum Volltext

Verfügbarkeit prüfen

P332 Risque d’hypoglycémie chez les patients traités par linagliptine, inhibiteur de la DPP4: données regroupées provenant de 1 489 patients diabétiques de type 2 (DT2) âgés de ≥ 65 ans

Diabetes & metabolism, 2015-03, Vol.41, p.A117-A118

2015

Link zum Volltext

Verfügbarkeit prüfen

Glucagon-like peptide 1 (GLP-1)

Molecular metabolism (Germany), 2019-12, Vol.30, p.72-130

2019

Link zum Volltext

Verfügbarkeit prüfen

Early insulin treatment in type 2 diabetes--no

Deutsche medizinische Wochenschrift (1946), 2013-05, Vol.138 (18), p.957

Nauck, M

2013

Link zum Volltext

Verfügbarkeit prüfen

Polypharmacy in people with Type 1 and Type 2 diabetes is justified by current guidelines-a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetes-associated problems

Diabetic medicine, 2014-09, Vol.31 (9), p.1078-1085

2014

Link zum Volltext

Verfügbarkeit prüfen

The Saliva Metabolome in Association to Oral Health Status

Journal of dental research, 2019-06, Vol.98 (6), p.642-651

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

Diabetes, obesity & metabolism, 2015-09, Vol.17 (9), p.849

2015

Link zum Volltext

Verfügbarkeit prüfen

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

Diabetologia, 2006-03, Vol.49 (3), p.452-458

2006

Link zum Volltext

Verfügbarkeit prüfen

Direct effect of GLP-1 infusion on endogenous glucose production in humans

Diabetologia, 2013-01, Vol.56 (1), p.156-161

2013

Link zum Volltext

Verfügbarkeit prüfen

Inkretinforschung und Inkretin-basierte Diabetestherapie

Diabetologe, 2017-11, Vol.13 (7), p.474-474

2017

Link zum Volltext

Verfügbarkeit prüfen

Cohort Profile: The Study of Health in Pomerania

International journal of epidemiology, 2011-04, Vol.40 (2), p.294-307

2011

Link zum Volltext

Verfügbarkeit prüfen

Reference intervals for serum concentrations of three bone turnover markers for men and women

Bone (New York, N.Y.), 2013-12, Vol.57 (2), p.399-404

2013

Link zum Volltext

Verfügbarkeit prüfen

Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data

Diabetes, obesity & metabolism, 2015-06, Vol.17 (6), p.581-590

2015

Link zum Volltext

Verfügbarkeit prüfen

GIP („Glucose-Dependent Insulinotropic Polypeptide“) und GLP-1 („Glucagon-Like Petide-1“)

Diabetologe, 2017-11, Vol.13 (7), p.475-481

2017

Link zum Volltext

Verfügbarkeit prüfen

Prospective Study of Serum 25-hydroxy Vitamin D and Tooth Loss

Journal of dental research, 2014-07, Vol.93 (7), p.639-644

2014

Link zum Volltext

Verfügbarkeit prüfen

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

Diabetes, obesity & metabolism, 2009-12, Vol.11 (12), p.1163-1172

2009

Link zum Volltext

Verfügbarkeit prüfen

Estimating the causal effect of body mass index on hay fever, asthma and lung function using Mendelian randomization

Allergy (Copenhagen), 2018-01, Vol.73 (1), p.153-164

2018

Link zum Volltext

Verfügbarkeit prüfen

Durability of glycaemic efficacy over 2years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

Diabetes, obesity & metabolism, 2014-11, Vol.16 (11), p.1111

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

International journal of clinical practice (Esher), 2009-01, Vol.63 (1), p.46-55

2009

Link zum Volltext

Verfügbarkeit prüfen

Messqualität von „low density lipoprotein cholesterol

Diabetologe, 2019, Vol.15 (1), p.13-18

2019

Link zum Volltext

Verfügbarkeit prüfen

Kappa free light chains in cerebrospinal fluid to identify patients with oligoclonal bands

European journal of neurology, 2018-09, Vol.25 (9), p.1134-1139

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 739

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(607)
Mit Volltextzugriff
(615)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(451)
Humans
(432)
Life Sciences & Biomedicine
(423)
Male
(272)
Female
(233)
Middle Aged
(203)
Biological And Medical Sciences
(198)
Adult
(180)
Endocrinology & Metabolism
(169)
Medical Sciences
(165)
Aged
(139)
Blood Glucose - Metabolism
(75)
Diabetes Mellitus, Type 2 - Drug Therapy
(74)
Endocrinopathies
(64)
Fundamental And Applied Biological Sciences. Psychology
(64)
Diabetes
(62)
Insulin - Blood
(62)
Risk Factors
(62)
Glucagon-Like Peptide 1
(61)
Internal Medicine
(59)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

CO-28: Comparaison de l'efficacité du liraglutide à celle du lixisenatide en ajout de metformine chez des patients diabétiques de type 2 : essai randomisé contrôlé de 26 semaines

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down

comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

P292 Efficacité et tolérance de l’adjonction du liraglutide à une insuline basale en comparaison au placebo chez des patients diabétiques de type 2 (résultats de l’essai randomisé contrôlé LIRA-ADD2BASAL)

P332 Risque d’hypoglycémie chez les patients traités par linagliptine, inhibiteur de la DPP4: données regroupées provenant de 1 489 patients diabétiques de type 2 (DT2) âgés de ≥ 65 ans

Glucagon-like peptide 1 (GLP-1)

Early insulin treatment in type 2 diabetes--no

Polypharmacy in people with Type 1 and Type 2 diabetes is justified by current guidelines-a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetes-associated problems

The Saliva Metabolome in Association to Oral Health Status

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

Direct effect of GLP-1 infusion on endogenous glucose production in humans

Inkretinforschung und Inkretin-basierte Diabetestherapie

Cohort Profile: The Study of Health in Pomerania

Reference intervals for serum concentrations of three bone turnover markers for men and women

Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data

GIP („Glucose-Dependent Insulinotropic Polypeptide“) und GLP-1 („Glucagon-Like Petide-1“)

Prospective Study of Serum 25-hydroxy Vitamin D and Tooth Loss

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

Estimating the causal effect of body mass index on hay fever, asthma and lung function using Mendelian randomization

Durability of glycaemic efficacy over 2years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

Messqualität von „low density lipoprotein cholesterol

Kappa free light chains in cerebrospinal fluid to identify patients with oligoclonal bands

Suchergebnisse filtern